Reassessing Immunotherapy Use in Advanced Renal Cell Carcinoma
There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were treated in the advanced setting.
Read More
ctDNA Testing May Offer Patients With RCC ‘Peace of Mind’
Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma.
Watch
Circulating Tumor DNA May Have Prognostic Value in Kidney Cancer
Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ctDNA.
